LONDON: Hikma Pharmaceuticals has agreed with Copenhagen based Xellia Pharmaceuticals to acquire parts of its US finished dosage form (FDF) business and assets, including a commercial portfolio and pipeline of differentiated products, a manufacturing facility in Cleveland, Ohio, sales and marketing capabilities, and an R&D center in Zagreb, Croatia.

Hikma will pay a cash consideration of $135 million, and an additional contingent consideration of up to $50 million, subject to the achievement of certain regulatory and commercial milestones.

The acquisition will enhances Hikma’s R&D capabilities. The R&D center in Zagreb, Croatia adds an experienced team of R&D professionals with the track record and expertise to develop complex finished dosage forms. Hikma will leverage this expertise across its global injectables markets

Neutral to Group core earnings in the first 12 months following closing and accretive thereafter, with meaningful longer-term benefits. Upon closing, the current Xellia in-market products will immediately contribute around $75 million revenue on an annualized basis.

The acquisition will add eight approved and marketed injectable products to Hikma’s US portfolio and 11 pipeline products. The Xellia commercial portfolio comprises the ready-to-use formulation, Vanco Ready® (vancomycin), launched in 2019, and other anti-infectives.

These products are currently manufactured by a third-party and Hikma will maintain these manufacturing contracts while it upgrades the Cleveland facility, with the goal of moving production of these products in-house.

The Cleveland site offers end-to-end capabilities to develop, manufacture, pack and distribute lyophilized vials and aseptically filled ready-to-use IV bag products. Hikma intends to undertake a series of investments to enhance productivity and efficiency through the addition of automation, equipment, and updated processes. These investments will be captured within Hikma’s existing annual capital expenditure plan. Hikma expects the facility to be operational within two to three years.

Hikma will also be acquiring Xellia’s R&D center in Zagreb, Croatia, including a large team of professionals.  This center will bring a range of expertise including developing innovative and generic products and finished dosage forms, primarily in premix RTU bags.

Riad Mishlawi, CEO commented: “Hikma has grown to become a top-three US supplier of sterile injectable medicines thanks to our strong record of successfully making value-enhancing acquisitions like this one. This acquisition will add significant scale to our US operations and will enhance our US injectable manufacturing capabilities and portfolio by adding complex technologies. I am confident that this transaction will deliver significant future value to our Injectables business, supporting growth over the medium term.”

Dr Bill Larkins, President of Hikma Injectables commented: “This acquisition strengthens our Injectables business, and I am particularly excited by the potential to further develop our pipeline with the talented and experienced team at the Zagreb R&D facility. The combination of Xellia’s assets with our quality manufacturing expertise and strong commercial capabilities puts us in an even stronger position to serve the growing needs of hospitals and patients.”

The transaction is subject to US Federal Trade Commission approval. Hikma’s 2024 guidance remains unchanged.